Pipeline
Our pipeline
Eight discovery programmes across five modalities and five therapeutic areas — each built on causal human biology and tested in our laboratory.
- Active discovery programmesPlaceholder
- 8
- Therapeutic modalities in development
- 5
Programmes
Explore the pipeline
Filter by modality or therapeutic area. Select a programme for its rationale and next milestone.
Showing 8 of 8 programmes
| Programme | Modality | Area | DiscoveryLead opt.PreclinicalClinical |
|---|---|---|---|
| AR-101Oral kinase inhibitor | Small molecule | Oncology | Preclinical |
| AR-204Immune-modulating antibody | Antibody | Immunology | Preclinical |
| AR-117Allosteric inhibitor | Small molecule | Oncology | Lead optimisation |
| AR-310Liver-targeted siRNA | siRNA | Cardiometabolic | Lead optimisation |
| AR-122CNS-penetrant small molecule | Small molecule | Neurology | Discovery |
| AR-215Tumour-targeting antibody | Antibody | Oncology | Discovery |
| AR-402mRNA protein-replacement | mRNA | Rare disease | Discovery |
| AR-501AAV gene therapy | Gene therapy | Rare disease | Discovery |
Co-develop a programme with us
Several programmes are open to partnering at discovery and lead-optimisation stage.